Iressa: profile and news

AstraZeneca's outgoing CEO got 60% pay hike in 2005 Feb 28, 2006
...million, compared with GBP1.411 million in 2004 when his remuneration was cut following setbacks with the company's anticoagulant Exanta and cancer drug Iressa ... - MarketWatch

Monogram Announces Year End 2005 Financial Results Feb 22, 2006
In conjunction with a Japanese collaborator, we presented the results of a study of tissue samples from 55 patients treated with Iressa(R). The correlations ... - MSN Money

Genes May Influence Response to Brain-Tumor Treatments Feb 26, 2006
Two drugs, Tarceva (erlotinib) and Iressa (gefitinib), have had some success in treating glioblastomas and have been approved for treating advanced lung cancer ... - Online - International News Network,

Addition of Erbitux® to Radiation Therapy Improves Survival in ... Feb 22, 2006
Previous studies have shown activity for Iressa®, another inhibitor of the EGFR pathway, for the treatment of head and neck cancers. ... - Cancer Consultants (press release),

AstraZeneca Withdraws Exanta Because of Liver Damage (Update5) Feb 14, 2006
The company's shares dropped 30 percent in 2004 as it struggled to introduce Iressa for cancer and the Crestor cholesterol medicine. ... - Bloomberg

AstraZeneca shares sink after drug is withdrawn Feb 15, 2006
The company was also forced to admit recently that its Iressa cancer treatment was unable to prolong the life of patients significantly. ... - ic Liverpool,

AstraZeneca pulls Exanta after liver injury case Feb 14, 2006
...among other issues. The group's lung cancer pill Iressa also failed to show survival benefits in a clinical trial in late 2004. - Scotsman,

Agency discloses '04 medicine deaths Jan 31, 2006
Of the 63 deaths, 12 were due to interstitial pneumonia from Iressa, a drug used for lung cancer, five from effects of the cancer drug Taxotere and four from ... - The Japan Times,

Lung Cancer Drug Pipeline Update Lists All 243 Drugs for Lung ... Feb 16, 2006
In the guideline of 2004 Iressa has been recommended as third line treatment of patients with locally advanced or metastatic NSCLC after failure of both ... - Genetic Engineering News,

New drug chief's priority to be a year of 'discovery' Feb 3, 2006
...find new blockbuster drugs after blood-thinning drug Exanta fell foul of US regulators in 2004 and the company later admitted that its Iressa cancer treatment ... - ic Liverpool,

Genzyme Launches Key Test to Monitor Gleevec(R) Resistance Feb 9, 2006
...factor receptor (EGFR) mutations have been shown to correlate with clinical response to certain drugs, including Tarceva(R) (erlotinib) and IRESSA(R) (gefitinib ... - International News Service,

AstraZeneca abandons blood thinner, citing risk Feb 15, 2006
The problems with Exanta, along with questions about its drug Iressa for cancer and Crestor for high cholesterol, had helped flatten AstraZeneca's stock in 2004 ... - philly.com,

Ambit Biosciences Expands Kinase Profiling Panel to 234 Kinases ... Feb 14, 2006
With more than 30 kinase inhibitors in clinical trials or approved for human use including Gleevec(R), IRESSA(R) and TARCEVA(TM), this important class of ... - Genetic Engineering News,

Reply to the Editor Feb 14, 2006
However, inhibitors of receptor tyrosine kinases such as epidermal growth factor receptor (Iressa, Tarceva) and platelet-derived growth factor receptor (Gleevec ... - The Journal of Thoracic and Cardiovascular Surgery

Cancer fight on target with new breed of drugs Feb 4, 2006
...the mortality rate in women who have HER2-positive early breast cancer; Glivec, currently being used to treat chronic myeloid leukaemia; and Iressa for lung ... - The Age,

Genzyme Launches Key Test to Monitor Gleevec(R) Resistance Feb 9, 2006
...receptor (EGFR) mutations have been shown to correlate with clinical response to certain drugs, including Tarceva® (erlotinib) and IRESSA® (gefitinib), used ... - Yahoo! News (press release)

Genzyme launches test to monitor Gleevec resistance Feb 13, 2006
...receptor (EGFR) mutations have been shown to correlate with clinical response to certain drugs, including Tarceva (erlotinib) and IRESSA (gefitinib), used in ... - News-Medical.net,

UPDATE 1-AstraZeneca profit leaps, Toprol key to 2006 Feb 2, 2006
...already taken steps to bolster the portfolio of new drugs, following the double setback of the failure of anti-clot pill Exanta and cancer drug Iressa in 2004. ... - Reuters

Heart drug clouds AstraZeneca prospects for 2006 Feb 2, 2006
...already taken steps to bolster the portfolio of new drugs following the double setback of the failure of anti-clot pill Exanta and cancer drug Iressa in 2004. ... - Reuters

AstraZeneca dragged down by heart drug fears Feb 2, 2006
The chief executive is working hard to bolster the portfolio of new drugs after two product failures - Exanta and the cancer drug Iressa in 2004. ... - Independent,

AstraZeneca Profit Boom Feb 2, 2006
Tenormin, Zestoretic, Zestril, Accolate, Bambec, Bricanyl, Oxis, Pulmicort, Rhinocort, Symbicort, Arimidex, Casodex, Faslodex, Iressa, Nolvadex, Tomudex ... - Spotlighting News

Genzyme Launches Key Test to Monitor Gleevec(R) Resistance 09 Feb 2006
...receptor (EGFR) mutations have been shown to correlate with clinical response to certain drugs, including Tarceva® (erlotinib) and IRESSA® (gefitinib), used ... - Yahoo! News (press release)

Today, There Are More Than 100 Companies Developing More Than 180 ... Jan 25, 2006
Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. ... - Genetic Engineering News,

Astra Zeneca on drugs spree Jan 28, 2006
Zeneca was badly hit by a series of setbacks at the end of 2004, which damaged the prospects of two potential blockbusters, the cancer drug Iressa and the blood ... - The Sunday Times,

Astrazeneca boss pledges to boost drugs pipeline Feb 2, 2006
...find new blockbuster drugs after blood-thinning drug Exanta fell foul of US regulators in 2004 and the company later admitted that its Iressa cancer treatment ... - Ireland Online,

Astrazeneca loses key patent case in US UPDATE Jan 18, 2006
Its prospects were hampered last year by the failure of lung cancer drug Iressa and the scrapping of anti-clotting agent Exanta on safety concerns. ... - Forbes

New cellular flaw found in some virulent breast cancers Jan 18, 2006
..."The development of cancer drugs like Gleevec and Iressa have shown that it is possible to block the action of kinases," said Sicinski, "so we hope that these ... - Innovations-Report,

Targeted drugs needed for breast cancer Jan 17, 2006
..."The development of cancer drugs like Gleevec and Iressa have shown that it is possible to block the action of kinases," said Researcher Peter Sicinski, "so we ... - United Press International

TODAY ON PHARMALIVE.COM Jan 23, 2006
...report explore how this can slow or even prevent an apparently effective from reaching the market, as was the case with AstraZeneca's lung cancer drug, Iressa. ... - PharmaLive.com (press release),

Lung cancer in women 12 Dec 2005
Researchers have found that lung cancer patients with mutations in EGFR tend to respond better to Iressa, one of the newer, targeted cancer therapies. ... - ITP.net,

Addition of Iressa® To Tarceva/Avastin Does Not Improve Outcomes ... Nov 15, 2005
Researchers from Sarah Cannon Research Institute have reported that the addition of Iressa® (gefinitib) to Tarceva® (erlotinib) and Avastin® (bevacizumab ... - Cancer Consultants (press release),

Results Encouraging with Interferon Alpha Plus Iressa (Gefitinib) ... Nov 22, 2005
PHILADELPHIA, PA -- November 22, 2005 -- In a phase 2 study of interferon alpha (IFN) plus either Gleevec (imatinib mesylate) or Iressa (gefitinib) in patients ... - DG News

New Data Show Survival Benefit for Arimidex(TM) in Early Breast ... Dec 9, 2005
CASODEX' (bicalutamide), 'FASLODEX' (fulvestrant), 'NOLVADEX' (tamoxifen), 'ZOLADEX' (goserelin), 'TOMUDEX' (raltitrexed) and 'IRESSA' (gefitinib) as well as a ... - news aktuell (Pressemitteilung),

Researchers probe links between gender and cancer Dec 8, 2005
He cites an example in lung cancer, when studies of Iressa, a targeted therapy for lung cancer, showed that patients with a particular genetic mutation ... - Pittsburgh Post Gazette,

Studies throw light on biomarkers which predict the subsets of ... Nov 16, 2005
The drug gefitinib (Iressa) was approved by the US Food and Drug Administration (FDA) in May 2003 under the agency’s accelerated approval program for the ... - Innovations-Report,

New Data Highlight Increased EGFR Gene Copy Number as the Most ... Nov 15, 2005
...an insight into a potential future direction for the targeted treatment of advanced non-small cell lung cancer (NSCLC) with the EGFR-TKI, gefitinib (IRESSA(TM ... - news aktuell (Pressemitteilung),

Genes May Influence Response to Brain-Tumor Treatments Nov 10, 2005
Two drugs, Tarceva (erlotinib) and Iressa (gefitinib), have had some success in treating glioblastomas and have been approved for treating advanced lung cancer ... - PakTribune.com,

Therapy Targets Brain Tumors Nov 10, 2005
Until now, doctors haven't been able to explain why the drugs Iressa and Tarceva help some patients but not others. The pills belong ... - CIO Today,

Monogram Presents Clinical Data on eTag(TM) Assay's Potential to ... Nov 15, 2005
...data demonstrating the ability of the company's eTag(TM) assays to predict treatment response for patients with lung cancer who receive Iressa® (gefitinib). ... - Yahoo! News (press release)

Glioblastoma Patients Who Respond to Targeted Therapy Identified Nov 12, 2005
The key to whether glioblastoma patients respond to targeted therapy with Tarceva (erlotinib) or Iressa (gefitinib) may be whether their tumors express two key ... - LaSalute.net,

UCLA discovery will aid in treatment of patients with a deadly ... Nov 11, 2005
Drugs such as Tarceva and Iressa target EGFR, blocking the cell signals that drive amplification of the protein and speed cancer growth. ... - Medical News Today (press release),

Pharma Reformulates Dec 5, 2005
...deficit hyperactivity disorder (ADHD) drug Strattera, Johnson & Johnson's (J&J) heart failure drug Natrecor, and AstraZeneca's lung cancer treatment Iressa. ... - Chemical & Engineering News

AZ shares boosted by cancer trial Nov 23, 2005
It could also help AstraZeneca to regain some of the ground it lost when trials of Iressa, another late-stage medicine against lung cancer, showed little ... - Times Online,

AstraZeneca starts lung cancer drug study Nov 23, 2005
...a successful trial of the anti-cancer compound will help it recoup lost ground following last year's failure of marketed lung cancer treatment Iressa in an ... - Life Style Extra,

Glioblastoma Patients Who Respond to Targeted Therapy Identified Nov 9, 2005
9 - The key to whether glioblastoma patients respond to targeted therapy with Tarceva (erlotinib) or Iressa (gefitinib) may be whether their tumors express two ... - MedPage Today,

Molecular Signature Identifies Druggable Glioblastomas 11/8/05 Nov 9, 2005
The epidermal growth factor receptor (EGFR) is commonly amplified in glioblastomas and drugs such as Tarceva (erlotinib) and Iressa (gefitinib) target EGFR ... - Drug Discovery & Development (subscription),

Treatment of acute myeloid leukemia with gefitinib: clinical ... Nov 8, 2005
Stegmaier K et al. (2005) Gefitinib (Iressa) induces myeloid differentiation of acute myeloid leukemia. Blood 106: 2841–2848 PubMed. ... - Nature.com (subscription),

Preliminary Results of Ongoing Phase II Study Show Early Promise ... Nov 16, 2005
Both studies met their primary endpoints.(4,5) - Trial 003, compared the anti-tumour effects of ZD6474 300mg monotherapy with gefitinib (IRESSA(R)) 250mg ... - APA OTS (Pressemitteilung),

UPDATE 1-Astra starts key study for new lung cancer drug Nov 23, 2005
...cancer compounds that could help AstraZeneca recover some of the ground it lost in oncology last year when its marketed lung cancer treatment Iressa failed in ... - Reuters

Tailoring Treatment for Brain Cancer Nov 9, 2005
They tested the technique in 26 patients who had either responded well or poorly to the standard EGFR blockers Tarceva or Iressa. ... - Ivanhoe,

AstraZeneca helps FTSE to new high Nov 23, 2005
Investors hope the drug will help AstraZeneca to recover some of the ground it lost after a setback last year, when its cancer drug, Iressa, failed in trials ... - Guardian Unlimited,

UT Southwestern Researchers Test Experimental Drug To Help Tiniest ... Nov 9, 2005
FDA Statement On Iressa (December 24, 2004) -- The Food and Drug Administration (FDA) has learned from AstraZeneca that a large clinical trial comparing Iressa ... - Science Daily (press release)

Albumin-bound Paclitaxel, Clofarabine and Erlotinib Expand ... Nov 14, 2005
...epithelial growth factor (EGF), "helping to spur cells to divide," Ms. Sisson said, likening the drug's action mechanism to that of Iressa (gefitinib) -- which ... - DG News

Genetic Analysis of Glioblastoma Brain Tumors Can Aid in Treatment ... Nov 10, 2005
...from recurrent malignant glioblastoma patients, 26 of whom responded either very well or very poorly to the drugs erlotinib (Tarceva®) and gefitinib (Iressa ... - National Institutes of Health (press release)

After 34 Years, Goals Change In Medicine's 'War On Cancer' Nov 11, 2005
...years. Other major drugs in the category include Novartis' (NVS) Gleevec, AstraZeneca's (AZN) Iressa and ImClone's (IMCL) Erbitux. ... - Investor's Business Daily (subscription)

AEterna Zentaris appoints a Board Vice Chairman, a New Chair of ... Nov 21, 2005
...he was involved in the early development of many of the agents now used routinely, including: Paclitaxel, Docetaxel, Gemcitabine, CPT-11, Iressa and Tarceva. ... - Yahoo! News (press release)

(PRN) - Jordan Melo 5.5 Comes to Life on the Streets of Baltimore ... Nov 15, 2005
Data Highlight Increased EGFR Gene Copy Number as the Most Positive Biomarker in Determining Which Patients are Most Likely to Benefit From gefitinib (Iressa(TM ... - Bolsamania.com,

Glioblastoma, screening for two gene variations can predict which ... Nov 14, 2005
...from recurrent malignant glioblastoma patients, 26 of whom responded either very well or very poorly to the drugs Erlotinib ( Tarceva ) and Gefitinib ( Iressa ... - Xagena.it,

Genetic analysis aids brain tumor treatment Nov 11, 2005
...(Tarceva(r)) and gefitinib (Iressa(r)). These two drugs belong to a class called EGFR (epidermal growth factor receptor) kinase inhibitors, and both are ... - myDNA.com,

Accelerated Approval Should Be Renamed "Conditional" Approval ... Nov 10, 2005
In the most recent test of the agency's accelerated approval enforcement, FDA limited use of AstraZeneca's Iressa to patients already benefiting from the ... - FDA Advisory Committee

Drugs' side effects need checks Nov 25, 2005
...harmful side effects. Iressa, a drug used to treat lung cancer, has side effects that led to the death of some patients. With clinical ... - Daily Yomiuri Online,

Pfizer's Troubles Pull Down Drugmakers Nov 21, 2005
...version of the same drug; the cardiovascular drug Plendil, which is suffering from generic competition in the US; and the cancer treatment Iressa, which US ... - Chemical & Engineering News

Array BioPharma to Present Phase IA Data From Anti-Cancer Compound ... Nov 8, 2005
Time Location: Pennsylvania Convention Center, Philadelphia, Pennsylvania Poster: "Combination Studies In Vitro and In Vivo with gefitinib (IRESSA) and the MEK1 ... - PR Newswire (press release),

FDA Orphan Drug Approvals: Zactima, Surfaxin, IL-21 Nov 8, 2005
Because the agent combines the action of gefitinib (Iressa, made by AstraZeneca) and erlotinib HCl (Tarceva, made by OSI Pharmaceuticals, Inc.) with an ... - Medscape (subscription)

ChemDiv, Inc. and ProQinase GmbH to Partner in Lead Discovery and ... Nov 7, 2005
...human tumors. Inhibitors of protein kinases, such as Gleevec, IRESSA and Tarceva, are recently approved anti-cancer drugs. The development ... - PR Newswire (press release),